MEIP Insider Trading
Insider Ownership Percentage: 3.12%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
MEI Pharma Share Price & Price History
Current Price: $2.87
Price Change: ▲ Price Increase of +0.1 (3.61%)
As of 01/17/2025 04:54 PM ET
MEI Pharma Insider Trading History
MEI Pharma Institutional Trading History
Data available starting January 2016
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Read More on MEI Pharma
Volume
18,720 shs
Average Volume
36,210 shs
Market Capitalization
$19.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.78
Who are the company insiders with the largest holdings of MEI Pharma?